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ABSTRACT The persistence of human immunodeﬁciency virus type-1 (HIV-1) has long been attributed to its high mutation
rate and the capacity of its resulting heterogeneous virus populations to evade host immune responses and antiviral drugs.
However, this view is incomplete because it does not explain how the virus persists in light of the adverse effects mutations in
the viral genome and variations in host functions can potentially have on viral functions and growth. Here we show that the
resilience of HIV-1 can be credited, at least in part, to a robust response to perturbations that emerges as an intrinsic property of
its intracellular development. Speciﬁcally, robustness in HIV-1 arises through the coupling of two feedback loops: a Rev-
mediated negative feedback and a Tat-mediated positive feedback. By employing a mechanistic kinetic model for its growth we
found that HIV-1 buffers the effects of many potentially detrimental variations in essential viral and cellular functions, including
the binding of Rev to mRNA; the level of rev mRNA in the pool of fully spliced mRNA; the splicing of mRNA; the Rev-mediated
nuclear export of incompletely-spliced mRNAs; and the nuclear import of Tat and Rev. The virus did not, however, perform
robustly to perturbations in all functions. Notably, HIV-1 tended to amplify rather than buffer adverse effects of variations in the
interaction of Tat with viral mRNA. This result shows how targeting therapeutics against molecular components of the viral
positive-feedback loop open new possibilities and potential in the effective treatment of HIV-1.
INTRODUCTION
Although it is well established that the high mutation rate of
human immunodeﬁciency virus type-1 (HIV-1), 104 ;105
mutations per base per replication round (1), provides an
effective means for the virus to evade antiviral drugs (2) and
host immune responses (3), it is not as widely appreciated that
high mutation rates can have adverse effects on viral growth
(4). Mutations may attenuate HIV-1 growth by altering, for
example, interactions of Rev or Tat with their regulatory
elements (5,6), RNA splicing of viral transcripts (7), and en-
zymatic activities of viral integrase (8), reverse transcriptase
(9), or protease (10,11). Given the many ways that frequent
deleterious mutations, acting alone or collectively, can impede
growth, how does HIV-1 persist? When mutations inactivate
some of its constitutive splice sites, HIV-1 can utilize al-
ternative splice sites (7,12–15) or activate new cryptic sites
(7). More generally, high recombination rates among different
HIV-1 strains can create new mosaic strains that grow better
than their parent precursors (16,17). We propose here an
intrinsic mechanism for HIV-1 persistence that is deﬁned by
the network of virus-host interactions required for its intra-
cellular growth. Speciﬁcally, we show how the coupling of
Rev and Tat feedbacks in their effects on HIV-1 (post-) tran-
scriptional regulation enable the virus to robustly respond to
changes in essential virus and cell functions.
The post-transcriptional regulation of HIV-1 enables the
virus to achieve a balanced expression of essential viral
components and optimize the production of progeny virions
(18–21). This regulation is mediated primarily by Rev, an
HIV-1 regulatory protein that serves as a sequence-speciﬁc
nuclear export factor for incompletely-spliced (full-length
and singly-spliced) mRNAs (22–32), and a temporal regu-
lator of their expression (18,21,33). Because this nuclear
export of incompletely-spliced mRNAs removes the nuclear
pool of precursors of fully spliced mRNA, causing a drop in
the nuclear and cytoplasmic levels of fully spliced mRNA
(29,34), the Rev activity creates over time a negative feed-
back loop, that at a late infection phase reduces the synthesis
of viral regulatory proteins, including itself (34,35). Another
regulatory protein, Tat, functions as a trans-activator. By
stabilizing the elongating transcription complex (36,37), Tat
dramatically increases the transcription of all viral mRNAs
including its own. Hence, the Tat activity creates a positive
feedback loop (38–40). Here we propose that these two feed-
back loops enable HIV-1 to adapt its growth to a diversity of
conditions, including genetically or environmentally altered
viral and cellular functions. Furthermore, in contrast to pre-
vious studies that have focused primarily on the regulatory
role played by Rev, we ﬁnd that the activity of Tat, when
coupled with the Rev-mediated negative feedback, plays
a signiﬁcant role in maintaining the robustness of HIV-1
growth.
MATERIALS AND METHODS
Infection cycle of HIV-1
After HIV-1 enters its host cell, released viral RNAs are reverse-transcribed
to produce a double-stranded DNA. This DNA is then transported into the
nucleus and integrated into the host genome, forming a provirus (41). Fig. 1
a schematically shows events following the provirus formation, RNA
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splicing, and (post-) transcriptional regulation. Transcription of the provirus
produces full-length (9 kb) HIV-1 mRNAs. This primary RNA transcript
then undergoes a series of splicing steps that yield the singly-spliced (4 kb)
and fully (or multipally)-spliced (2 kb) classes of mRNAs, deﬁned by more
than 30 distinct mRNA species (7,13,14,42–44). The incompletely-spliced
mRNAs primarily encode viral structural proteins. For example, full-length
mRNA encodes Gag and Gag/Pol, and singly-spliced mRNA encodes Vif,
Vpr, Tat, Vpu, and Env. In contrast, fully spliced mRNA primarily encodes
viral regulatory proteins, such as Tat, Rev, and Nef. Initially, only fully
spliced mRNA is exported to the cytoplasm, whereas full-length and singly-
spliced mRNAs are retained in the nucleus and spliced to completion
(23,25,29–31). After being expressed in the cytoplasm, Rev and Tat proteins
are imported into the nucleus. Tat functions in the nucleus as a transactiv-
ator to increase synthesis of full-length mRNA. Once Rev is imported into
the nucleus, it binds to each Rev response element (RRE) of incompletely-
spliced HIV-1 mRNAs (30,45,46). A Rev monomer ﬁrst binds to the high-
afﬁnity site of each RRE, after which additional Rev monomers assemble
progressively along the length of the low-afﬁnity sites (28,47–51). Once
a critical threshold level of RRE-bound Rev is reached (28,49,52), the Rev-
RNA complexes are actively exported to the cytoplasm. Thus, Rev functions
in the nucleus as a positive regulator of the expression of intron-containing
(or incompletely-spliced) viral messages. Once the Rev-RNA complex
reaches the cytoplasm, either the RNA is translated to yield viral structural
proteins or, in the case of full-length RNA, it may also be packaged into
a progeny virion as a RNA genome (41, 53). The released cytoplasmic Rev
is then recycled back to the nucleus for a subsequent round of export.
Therefore, the level and timing of HIV-1 mRNA expression are regulated
entirely at the (post-) transcriptional level by Tat and Rev proteins.
Mathematical model and computational methods
To develop insights into how HIV-1 achieves robust growth we employ here
a mechanistic kinetic model. Models have been previously developed to
study various aspects of HIV-1 intracellular growth (54–56), but they have
lacked sufﬁcient detail to offer insight into potential mechanisms of HIV-1
robustness. We have recently developed a detailed mechanistic model for
HIV-1 growth with a focus on events that follow integration of the provirus
(57). The model accounts for basal-level cellular transcription from pro-
viral DNA, successive steps of RNA splicing, Rev-mediated and Rev-
independent nuclear export of mRNAs, translation and shuttling of Rev and
FIGURE 1 RNA splicing and (post-) tran-
scriptional regulation processes of HIV-1
and its response to perturbations in viral
and cellular functions. (a) Real virus. (b)
Reference virus. Real HIV-1 adapts the
cytoplasmic proﬁles of singly- and fully
spliced mRNAs to a diversity of conditions,
whereas the reference virus does not.
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Tat back to the nucleus, their respective feedbacks on transcription, a Rev
threshold for nuclear export, and Rev-mediated inhibition of splicing, as
shown schematically in Fig. 1 a. We employ the model here to probe how
intracellular HIV-1 growth may be inﬂuenced by perturbations in viral and
cellular functions, comparing the behavior of the simulated virus with the
behavior of a reference virus. Perturbations to viral and cellular functions
were implemented in silico as described previously (58,59). A detailed de-
scription of the model and a complete list of parameters used are provided in
the Appendices.
To better appreciate the roles of the Rev and Tat regulatory feedbacks in
HIV-1 growth, we also deﬁned an open-loop reference virus where we
suspended the Rev and Tat feedbacks. To simulate this reference virus, we
ﬁrst ran the full closed-loop simulation (including all feedbacks) using our
base-case set of virus and host parameters. Next, we captured and saved
from this full simulation the resulting dynamic proﬁles of singly-spliced
and fully spliced HIV-1 mRNA accumulation in the cytoplasm. We then
imposed these mRNA proﬁles on all open-loop simulations, independent
of changes to virus or host parameters, as shown schematically in Fig. 1 b.
Two points are important to note. First, the open-loop reference virus
behaves identically with the closed-loop virus for base-case parameter
values. Second, feedbacks are suspended at the step of nuclear export of
singly- and fully spliced mRNA, so the cytoplasmic proﬁles of singly-
spliced and fully spliced HIV-1 mRNA for the reference virus remain
always the same.
We simulated two days of growth for both the closed-loop (real) and
open-loop (reference) HIV-1, and we used these results to calculate the
cumulative production of different HIV-1 mRNA or proteins, guided by the
following rationale. To produce viral progeny, full-length mRNA and viral
structural proteins expressed from full-length and singly-spliced mRNA
must be packaged into relatively stable progeny virions before they are
degraded in the cytoplasm. Therefore, time-cumulative yields of these
incompletely-spliced mRNAs in the cytoplasm, rather than their levels at
a ﬁxed time point, should better correlate with actual yields of HIV-1
progeny virions. The dynamic behavior of Rev and Tat is more complex
because Rev continuously shuttles between the nucleus and the cytoplasm,
generally with faster rates of import than export (60–62), whereas Tat is
imported to the nucleus, and they have different half-lives in different com-
partments (63). Thus, the levels of Rev and Tat in the nucleus will generally
differ from their levels in the cytoplasm. Furthermore, for a given com-
partment, protein levels for different viral or cellular parameters will highly
depend on the speciﬁc time-point considered. Therefore, we also char-
acterized the overall behavior of Rev and Tat by their time-cumulative pro-
duction rather than by their levels at a ﬁxed time-point.
RESULTS AND DISCUSSION
Rev-mRNA binding constant and fraction
of Rev-expressing mRNA
We ﬁrst studied how HIV-1 would respond to mutations that
alter the formation of protein-RNA complexes, speciﬁcally
between the Rev protein and the Rev response element
(RRE) of viral mRNA. We simulated the effects of such
mutations by altering the Rev-mRNA binding constant over
a range from 0.01 to 10 times its base-case value and by
changing the fraction of the Rev-expressing mRNA (rev
mRNA) in the fully spliced mRNA pool, a value that directly
impacts the level of available Rev protein. We changed this
fraction from 0.4 to 2 times its base-case value; the fraction
of nef mRNA in the pool was correspondingly modiﬁed,
whereas the fraction of tat mRNAwas maintained at its base-
case value. Fig. 2 shows the simulated behaviors of real and
FIGURE 2 Responses of real and reference HIV-1 to perturbations in the
Rev-mRNA binding afﬁnity and the fraction of the rev mRNA in HIV-1
mRNA pool. (a) Time-cumulative yield of full-length mRNA in the
cytoplasm. Time-cumulative production of (b) Tat and (c) Rev. Simulated
behaviors for real and reference HIV-1 are indicated by solid and open
surfaces, respectively, and the base-case behavior shared by both viruses is
indicated by an 3 symbol. The results were obtained at two days’ post-
infection. The Rev binding afﬁnity is plotted on the y axis, shown
quantitatively as the base-10 log of the ratio of the Rev binding constant to
its base-case value. Hence, the Rev binding constant ranges from 0.01- to
10-fold of its base-case value.
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reference HIV-1, denoted by solid and open surfaces,
respectively, where the base-case behavior shared by both
viruses is indicated by an ‘‘3’’ symbol. Mutations that
reduce the Rev binding constant or the fraction of rev mRNA
act to directly reduce (cumulative) yields of full-length
mRNA in the cytoplasm for both viruses (Fig. 2 a). By
making productive Rev-mRNA interactions weaker or less
frequent, they shift the dynamic equilibrium among free and
Rev-bound mRNAs in the nucleus toward free mRNA. This
enhances splicing of full-length mRNA, while also reducing
the Rev-mediated transport of the full-length mRNA from
the nucleus. In the case of real HIV-1, such mutations also
foster production of singly- and fully spliced mRNAs in the
nucleus by enhancing splicing of full-length mRNA.
Although the mutations could delay the initiation of nuclear
export of singly-spliced mRNA, the effect of its enhanced
production in the nucleus dominates, increasing its cumula-
tive yield in the cytoplasm. Similarly, enhanced production
of fully spliced mRNA in the nucleus increases its cyto-
plasmic yield. Therefore, compared to reference HIV-1,
expression of both Tat and Rev proteins is enhanced, as
shown in Fig. 2, b and c, respectively. Feedback of Tat and
Rev proteins to the nucleus then enhances synthesis of full-
length mRNA and facilitates its export to the cytoplasm,
respectively, compensating in part for direct depletion of
full-length mRNA in the cytoplasm. Consequently, the
cytoplasmic cumulative level of full-length mRNA for real
HIV-1 responds less sensitively to these mutations than for
the reference virus, as shown in Fig. 2 a.
In contrast, as the Rev binding constant or the fraction of
rev mRNA increases to values above its base-case value, the
dynamic equilibrium among free and Rev-bound mRNAs
in the nucleus is shifted toward a higher Rev-bound mRNA.
This reduces splicing of full-length mRNA, while also
enhancing the Rev-mediated transport of the full-length
mRNA from the nucleus, which directly enhances (cumula-
tive) yields of full-length mRNA in the cytoplasm for both
viruses. In the case of real HIV-1, however, such mutations
also reduce production of singly- and fully spliced mRNAs in
the nucleus. This generally reduces yields of both singly- and
fully spliced mRNAs in the cytoplasm, although the nuclear
export of singly-spliced mRNA is initiated slightly earlier,
and expression of both Tat and Rev proteins is thereby
reduced, as shown in Fig. 2, b and c, respectively. Reduced
expression of Tat and Rev then act through regulatory
feedbacks to reduce synthesis of full-length mRNA in the
nucleus and decelerate its enhanced export to the cytoplasm,
respectively, allowing its cumulative level in the cytoplasm
to persist with less change than found for the reference virus,
as shown in Fig. 2 a. This mechanism may help HIV-1 to
prevent the overproduction of full-length mRNA in the
cytoplasm (Fig. 2 a), while reducing the loss of singly-spliced
mRNA in the cytoplasm (not shown). HIV-1 could thereby
maintain the balance between the Gag and Env expression,
a balance that is essential for HIV-1 growth (19,20).
mRNA splicing rate and Rev export threshold
We next investigated how HIV-1 responds to perturbations
in the mRNA splicing rate and the threshold level (Th) of
Rev required for nuclear export of full-length mRNA and
singly-spliced mRNA. The splicing rate may be affected by
a viral mutation that alters the splicing efﬁciency of a cis-
acting viral sequence or induces an alternative splicing
pattern with a different splicing efﬁciency. Moreover, the
splicing rate could be also affected by a change in the
availability or activity of the trans-acting cellular splicing
machinery, reﬂecting the identity or physiological state of
the host cell. A variation in the Rev export threshold may be
mediated by perturbations in the availability and activity of
the cellular exportin family. We varied the splicing rate over
a range from 0.1 to 10 times its base-case value and the Rev
export threshold over a range from 3 to 11 Rev monomers
required per RRE (28,49).
As the splicing rate increases to values above its base-case
value, the chance for full-length mRNA to exit the nucleus
before being further spliced is reduced, giving lower cyto-
plasmic (cumulative) yields for both the real and the ref-
erence viruses (Fig. 3 a). In the case of real HIV-1, the
production of singly-spliced mRNA in the nucleus also
generally increases, leading to its higher cytoplasmic yield
(not shown). However, for very high splicing rates, cyto-
plasmic yields of singly-spliced mRNA then fall, like the
yields for the full-length species. Mechanistically, these
yields fall because the negative effect of growing instability
of singly-spliced mRNA in the nucleus dominates the posi-
tive effect arising from its enhanced production. Further, as
the splicing rate increases, the production of fully spliced
mRNA in the nucleus is initiated earlier and at a higher rate,
due to a reduced stability of its precursor mRNAs, leading to
an earlier rise and increased cytoplasmic yield (not shown).
Therefore, the expression of both Tat and Rev are enhanced
at higher splicing rates, as shown in Fig. 3, b and c. This is
true even when splicing is excessively fast because the
enhanced Tat expression from fully spliced mRNA com-
pensates for the reduction in the Tat expression from singly-
spliced mRNA. Enhancement of Tat and Rev expression
then feed-back to exert compensatory effects on the dy-
namics of cytoplasmic full-length mRNA. Tat enhances its
synthesis in the nucleus, and Rev facilitates its nuclear ex-
port and splicing inhibition. Here, as before, the effects of a
mutation in real HIV-1 elicit direct and indirect system-level
responses that, by affecting the cytoplasmic level of full-
length mRNA in opposing directions, contribute to a robust
response. This response is shown in Fig. 3 a for higher-than
base-case splicing rates by the more gentle drop in cumulative
full-length mRNA for real virus than reference virus.
If mutations cause the splicing rate to fall relative to the
base case, the chance for full-length mRNA to exit the
nucleus before being further spliced increases, leading to its
enhanced cytoplasmic yield, shown by the plateau region of
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Fig. 3 a. In the case of real HIV-1, however, the production
of singly- and fully spliced mRNA in the nucleus is si-
multaneously reduced, causing their cytoplasmic yields to
drop. The resulting reductions in the expression of Tat and
Rev (Fig. 3, b and c) then act to reduce synthesis of full-length
mRNA in the nucleus and decelerate its enhanced nuclear
export, respectively. If the mutation causes splicing to become
excessively slow, however, the negative effects of a reduced
nuclear export and synthesis of full-length mRNA dominate
the positive effect of its enhanced stability, causing its cy-
toplasmic yield to drop (Fig. 3 a). These results suggest the
existence of a range of splicing rates that will enable HIV-1 to
optimize its growth in different host environments.
As the threshold for Rev export increases the cytoplasmic
yield of full-length mRNA slightly but monotonously de-
creases for both the real and the reference viruses, as shown
in Fig. 3 a, most apparent when splicing rates are below the
base-case value. This relationship arises because more Rev is
required for the export of full-length mRNA and more time is
required for the higher Rev threshold to be reached, so full-
length mRNA stays longer in the nucleus and is further
spliced at the expense of its nuclear export. In the case of
real HIV-1, the production of singly-spliced mRNA in the
nucleus is simultaneously increased. However, for earlier
stages of the HIV-1 life cycle, this increase is not directly
translated into an enhanced cytoplasmic yield of singly-
spliced mRNA because more Rev is required for its export.
Nevertheless, singly-spliced mRNA eventually reaches its
higher cytoplasmic level, and irrespective of the export
threshold, its cumulative yields at later stages of the life cycle
are quite similar (not shown). Due to the increased singly-
spliced mRNA in the nucleus and its longer nuclear re-
tention, however, the production of fully spliced mRNA
always increases, leading to its enhanced cytoplasmic yield
and therefore an enhanced expression of Rev (Fig. 3 c). In
the case of Tat, because its expression depends on both
singly- and fully spliced mRNA, higher export thresholds
can slightly reduce its expression early in the growth cycle.
However, its expression level rapidly recovers (Fig. 3 b),
leading to an enhanced Tat transactivation, although the
transactivation eventually saturates (not shown). Together, the
enhanced expression of Tat and Rev then compensate for in-
creased splicing of full-length mRNA by enhancing its syn-
thesis and slightly facilitating its nuclear export, respectively,
though this subtle effect is barely distinguishable in Fig. 3 a.
Nuclear import rate
Finally, we investigated the HIV-1 response to a perturbation
in the import rate, where the same rate constants were as-
sumed for both Tat and Rev. A variation in the import rate
may be caused either by perturbations in the activity and
availability of the cellular importin family, or by a viral
mutation that directly alters the interaction of Rev and Tat
with the importin family while indirectly changing the
FIGURE 3 Responses of real and reference HIV-1 to perturbations in the
mRNA splicing rate and the Rev export threshold. (a) Time-cumulative
yield of full-length mRNA in the cytoplasm. Time-cumulative production of
(b) Tat and (c) Rev. Simulated behaviors for real and reference HIV-1 are
indicated by solid and open surfaces, respectively, and the base-case be-
havior shared by both viruses is indicated by an3 symbol. The results were
obtained at two days’ post-infection. The mRNA splicing rate is plotted on the
x axis, shown quantitatively as the base-10 log of the ratio of the splicing rate
constant to its base-case value. Hence, the splicing rate constant ranges from
0.1- to 10-fold of its base-case value.
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import rate. Fig. 4 a shows the time proﬁles for the level (not
cumulative yield) of cytoplasmic full-length mRNA for
different import rates. Simulated trajectories for real HIV-1
and the reference virus are indicated by solid and dotted
lines, respectively. The reference virus always exhibited the
same cumulative production proﬁles for Tat and Rev (Fig. 4,
b and c), corresponding to those obtained at the base-case
value, since the cytoplasmic accumulation proﬁles of singly-
and fully spliced mRNA remain the same, irrespective of the
import rate.
As the import rate decreases, the cytoplasmic yields of
full-length mRNA for both real HIV-1 and the reference
virus monotonically decrease, with a delayed initial rise, as
shown in Fig. 4 a. Here, slower import of Rev to the nucleus
restricts the nuclear export and splicing inhibition of full-
length mRNA, providing it more time to be spliced. In
addition, a slower import of Tat delays and reduces Tat tran-
sactivation. In the case of real HIV-1, however, the pro-
duction of singly-spliced mRNA in the nucleus is less
inhibited, though its initial rise is slower due to the reduced
Tat supply. Therefore, lower import rates cause a delay in the
initial rise of cytoplasmic singly-spliced mRNA (Rev effect)
and slow its subsequent rise (both Rev and Tat effect);
however, it eventually attains a higher cytoplasmic level than
it would at the base-case import rate (not shown). Similarly,
despite a slower initial rise of fully spliced mRNA in the
nucleus it eventually attains higher cytoplasmic levels rel-
ative to the base case (not shown). Accordingly, as shown
in Fig. 4, b and c, lower import rates cause slower initial rises
of both Tat and Rev; however, their rise rates eventually
become faster than their corresponding values for the base-
case import rate. These then compensate for the initial
reduction in the synthesis of full-length mRNA and facilitate
the nuclear export and splicing inhibition of full-length
mRNA. Furthermore, because Tat and Rev are much more
stable in the nucleus than in the cytoplasm (63), their losses
by degradation increase as the import rate decreases. The en-
hanced production of Tat and Rev may also compensate for
these losses. Consequently, as shown in Fig. 4 a, although the
initial rises of cytoplasmic full-length mRNA for real HIV-1
are delayed compared to those for the reference virus, real
HIV-1, with its responsive feedback of Tat and Rev, eventually
yields higher levels of cytoplasmic full-length mRNA.
For higher import rates, the cytoplasmic yields of full-
length mRNA for both the real and reference HIV-1 mono-
tonically increase, with an earlier initial rise, as shown in Fig.
4 a. As in the previous cases, real HIV-1 acts to maintain its
growth robustness by decelerating an enhanced nuclear ex-
port of full-length mRNA and also reducing its new synthe-
sis. However, at the current base-case value of the import rate
FIGURE 4 Responses of real and reference HIV-1 to perturbations in the
import rate of Tat and Rev. (a) Time proﬁles for the level (not cumulative
yield) of cytoplasmic full-length mRNA. Time-cumulative production of (b)
Tat and (c) Rev. Simulated trajectories for real and reference HIV-1 are
indicated by solid and dotted lines, respectively. The reference virus always
exhibits the same cumulative production proﬁles for Tat and Rev (b and c),
corresponding to those obtained at the base-case value. The number on each
curve denotes the base-10 logarithm of the ratio of the import rate constant
to its base-case value. Hence, the import rate constant ranges from 0.01- to
10-fold of its base-case value.
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constant, equal to 10 times the export rate constant, the effect
of this robustness mechanism is negligible.
Design of anti-HIV therapies
Our results have implications for the design of anti-HIV
therapies. Speciﬁcally, they suggest one seek to identify and
target molecular components that are not controlled by, or
perhaps even act against, the robustness function. Consider,
for example, how HIV-1 would respond to mutations that
alter the equilibrium constant between the Tat protein and
the Tat (or transactivation) responsive element (TAR) of the
viral mRNA. As the Tat equilibrium constant decreases to
values below its base-case value, the level of Tat trans-
activation and thus the synthesis of full-length mRNA in the
nucleus are reduced, leading further to reduced cytoplasmic
(cumulative) yields of full-length mRNA for both the real
and the reference viruses, as shown in Fig. 5 a. Here simu-
lated behaviors for real and reference HIV-1 are indicated by
solid and dotted lines, respectively, and the base-case be-
havior shared by both viruses is indicated by an ‘‘3’’
symbol. In the case of real HIV-1, such mutations also re-
duce the production of both singly- and fully spliced mRNAs
in the nucleus. Reduced production of fully spliced mRNA
then reduces its yield in the cytoplasm and thereby reduces
Rev expression (Fig. 5 c), which further restricts the nuclear
export of full-length and singly-spliced mRNAs and thereby
reduces their cytoplasmic yields. Then reduced cytoplasmic
yields of both singly- and fully spliced mRNA reduce the
expression of Tat (Fig. 5 b). Feedback of Tat and Rev
proteins to the nucleus then reduces further synthesis of full-
length mRNA and its export to the cytoplasm, respectively,
and thereby creates a positive feedback loop. This response
is shown in Fig. 5 a for a lower-than base-case equilibrium
constant by the more rapid drop in cumulative full-length
mRNA for the real virus than for the reference virus. Sim-
ilarly, HIV-1 would respond to any antiviral action that reduces
the Tat equilibrium constant in a way that would aggravate its
growth by amplifying the decrease in the expression of Tat and
Rev. Hence, targeting viral or cellular molecular components
that induce positive-feedback loops may well exhibit more
potent antiviral activities than strategies that target robustly
maintained functions. Further, such a strategy should have
potential for the treatment of a wide range of viruses, with an
emphasis on those that have a similar regulatory mechanism.
CONCLUSIONS
Our results here suggest that HIV-1 may have evolved to main-
tain its stable growth against mutational- or environmentally
FIGURE 5 Responses of real and reference HIV-1 to perturbations in the
Tat-mRNA binding afﬁnity. (a) Time-cumulative yield of full-length mRNA
in the cytoplasm. Time-cumulative production of (b) Tat and (c) Rev.
Simulated behaviors for real and reference HIV-1 are indicated by solid and
dotted lines, respectively, and the base-case behavior shared by both viruses
is indicated by an 3 symbol. The results were obtained at two days’ post-
infection. The Tat binding afﬁnity is plotted on the x axis, shown quan-
titatively as the base-10 log of the ratio of the Tat equilibrium constant to its
base-case value. Hence, the Tat equilibrium constant ranges from 0.01- to
10-fold of its base-case value.
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caused variations in viral and cellular parameters, and its
(post-) transcriptional regulation process, mediated by both
Tat and Rev, is responsible for this robustness of HIV-1
growth. Given a relatively small-sized genome and a limited
number of molecular components, HIV-1 may have evolved
this compact but multi-purpose mechanism to simultaneo-
usly satisfy a range of survival criteria including, but not
limited to, a balanced expression of each viral component,
optimal virion production, and growth robustness.
Robustness is a potentially ubiquitous feature of living
systems that enables them to reliably perform essential tasks
in the face of the perturbations in their internal parameters or
their external environments (64–67). This property may arise
from the complex interconnection of intracellular genetic and
biochemical networks (64,65). However, we have shown here
that a minimal network in HIV-1 growth, deﬁned by inter-
actions between only two feedback loops, one negative (Rev)
and one positive (Tat), exhibits robust behavior. Moreover,
unlike cellular robustness, where an understanding of the un-
derlying molecular interactions is limited, our analysis of
HIV-1 post-transcriptional regulation reveals how networks
deﬁned by a small number of components and interactions can
exhibit robustness. By identifying and characterizing robust-
ness in other minimal networks, one may begin to unveil its
principles and mechanisms in more complex biological
systems.
APPENDIX 1: MATHEMATICAL MODEL FOR
HIV-1 INTRACELLULAR GROWTH
dFN=dt ¼ ðTcb1 Tcadd 3 KTat 3 TN=ð11KTat 3 TNÞÞ 3 PV
1 kð1Þd 3 FR
ð1Þ
N  ðkFsp1 kRNAdeg;N1 kð1Þa 3 RNÞ 3 FN: (1)
dSN=dt¼ kFsp3FN1kð1Þd 3SRð1ÞN ðkSsp1kRNAdeg;N1kð1Þa 3RNÞ3SN:
(2)
dMN=dt ¼ kSsp 3 SN1 +
sn
i¼1
ð1 dS;ðiÞÞ 3 kSsp 3 SRðiÞN
 
 ðkMexp1 kRNAdeg;NÞ 3 MN: (3)
dFC=dt ¼ +
sn
i¼1
kF;ðiÞexp 3 FR
ðiÞ
N
 
 kRNAdeg;C 3 FC: (4)
dSC=dt ¼ +
sn
i¼1
k
S;ðiÞ
exp 3 SR
ðiÞ
N
 
 kRNAdeg;C 3 SC: (5)
dMC=dt ¼ kMexp 3 MN  kRNAdeg;C 3 MC: (6)
dFR
ðiÞ
N =dt ¼ kðiÞa 3 RN 3 FRði1ÞN 1 kði11Þd 3 FRði11ÞN
 ðkðiÞd 1 kði11Þa 3 RN1 kF;ðiÞexp 1 ð1 dF;ðiÞÞ 3 kFsp
1 kRNAdeg;NÞ 3 FRðiÞN ðfor i ¼ 1 . . . snÞ: (7)
dSR
ðiÞ
N =dt ¼ kðiÞa 3 RN 3 SRði1ÞN 1 kði11Þd 3 SRði11ÞN
1 ð1 dF;ðiÞÞ 3 kFsp 3 FRðiÞN  ðkðiÞd 1 kði11Þa 3 RN1 kS;ðiÞexp
1 ð1 dS;ðiÞÞ 3 kSsp1 kRNAdeg;NÞ 3 SRðiÞN ðfor i ¼ 1 . . . snÞ:(8)
dRC=dt ¼ fRev 3 Tr 3 fMrev 3 MC1 kRexp 3 RN
1 +
sn
i¼1
i 3 ðkF;ðiÞexp 3 FRðiÞN 1 kS;ðiÞexp 3 SRðiÞN Þ
 
 ðkRimp1 kProdeg;CÞ 3 RC: (9)
dTC=dt ¼ fTat 3 Tr 3 f Stat 3 SC1 fMtat 3 MC
 
1 kTexp 3 TN
 ðkTimp1 kProdeg;CÞ  TC: (10)
dRN=dt ¼ kRimp 3 RC1+
sn
i¼1
k
ðiÞ
d 3ðFRðiÞN 1 SRðiÞN Þ
 
1 +
sn
i¼1
k
RNA
deg;N

3 i 3ðFRðiÞN 1 SRðiÞN Þ

1+
sn
i¼1
ð1 dS;ðiÞÞ 3 kSsp 3 i 3 SRðiÞN
 
 +
sn
i¼1
k
ðiÞ
a 3ðFRði1ÞN 1 SRði1ÞN Þ
 
1 kRexp1 k
Pro
deg;N
 
3RN:(11)
dTN=dt ¼ kTimp 3 TC  ðkTexp1 kProdeg;NÞ 3 TN: (12)
APPENDIX 2: NOMENCLATURE
FN, FC Full-length mRNA in the nucleus and cytoplasm,
respectively.
SN, SC Singly-spliced mRNA in the nucleus and cytoplasm,
respectively.
MN, MC Fully (or multipally)-spliced mRNA in the nucleus and
cytoplasm, respectively.
RN, RC Rev in the nucleus and cytoplasm, respectively.
TN, TC Tat in the nucleus and cytoplasm, respectively.
FR
ðiÞ
N (i) Rev-bound form of full-length mRNA in the
nucleus, where FR
ð0Þ
N ¼ FN:
SR
ðiÞ
N (i) Rev-bound form of singly-spliced mRNA in the
nucleus, where SR
ð0Þ
N ¼ SN:
sn Maximum number of Rev monomers per RRE.
Th Threshold number of Rev for nuclear export of
Rev-RNA complexes.
Tcb Basal transcription rate for HIV-1.
Tcadd Increase in HIV-1 transcription by Tat transactivation.
Tr Steady-state translation rate.
kFsp Splicing rate constant for the ﬁrst splicing (from
full-length to singly-spliced mRNAs).
kSsp Splicing rate constant for the second splicing (from
singly-spliced to fully spliced mRNAs).
dF,(i) Splicing delay factor for the splicing from FR
ðiÞ
N
to SR
ðiÞ
N :
dS,(i) Splicing delay factor for the splicing from SR
ðiÞ
N to MN.
k
F;ðiÞ
exp ; k
S;ðiÞ
exp ; kMexp Nuclear export rate constants for FR
ðiÞ
N ; SR
ðiÞ
N ; and MN,
respectively.
kRexp; k
T
exp Nuclear export rate constants for Rev and Tat,
respectively.
kRimp; k
T
imp Nuclear import rate constants for Rev and Tat,
respectively.
k
ðiÞ
a Association constant for the binding of Rev and FR
ði1Þ
N
(or SR
ði1Þ
N Þ:
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APPENDIX 3: MODEL DESCRIPTION
The model describes the RNA splicing and (post-) transcriptional regulation
processes of HIV-1 shown schematically in Fig. 1 a. Events that precede the
initial round of HIV-1 transcription, such as reverse-transcription of viral
RNAs, nuclear transport of the viral DNA, and its integration into the host
genome, are described by reported ﬁxed-time delays based on experimental
observations (68–70). In our simulation we assumed one provirus per cell
was produced 12 h after entry.
Full-length mRNA (FN) is ﬁrst synthesized in the nucleus by cellular
base-level transcription, and its synthesis is accelerated by Tat trans-
activation as the level of nuclear Tat (TN) increases (Eq. 1). The base-level
transcription rate (Tcb) was approximated by dividing a typical eukaryotic
RNA polymerase elongation rate, 40 bases/s (71), by the length of HIV-1
RNA genome, 9500 bases (72). We used Michaelis-Menten expressions to
describe the Tat transactivation and its saturation kinetics, caused either by
the limitation in the number of polymerases simultaneously attached to
a single provirus, or by limiting host co-factors of Tat. We assumed
transcription rates could be activated up to 100-fold (73–75). Full-length
mRNA undergoes a series of alternative splicing events in the nucleus to
yield singly-spliced mRNA (SN) and fully spliced mRNA (MN). We
modeled the RNA splicing as a two-step process that ﬁrst converts full-
length mRNA to a singly-spliced intermediate (the ﬁrst splicing), which is
then further converted to fully spliced mRNA (the second splicing), as
shown in Fig. 1 a. First-order kinetics are assumed for both the ﬁrst and
second splicing processes (Eqs. 2 and 3), and the same splicing rate con-
stants (kFsp ¼ kSsp) are assumed unless otherwise speciﬁed. It has been
reported that the overall RNA splicing process of HIV-1 is completed within
2 h (76), which corresponds to ksp. 1 molecule/h. However, due to the lack
of direct measurements of the splicing rate constant, observations made on
adenovirus type-2 have been adopted, which is one molecule per 20–30 min
(or 2–3 molecules/h) (54,77). This value may serve as an upper bound for
HIV-1 splicing rate constant, since HIV-1 encodes intrinsically inefﬁcient
splice sites (30,78,79) that make processing of HIV-1 RNA less efﬁcient
than the processing of cellular or other viral RNAs. The incompletely-
spliced mRNAs (FN and SN) are in dynamic equilibrium with their cor-
responding 1:1 Rev-RNA complexes, FR
ðiÞ
N and SR
ðiÞ
N ; as shown in Eqs. 1
and 2. The superscripts of FR
ðiÞ
N and SR
ðiÞ
N denote the number (i) of Rev
monomers bound to the full-length and singly-spliced mRNAs, respectively.
We assumed that up to 12 Rev monomers (sn ¼ 12) can bind to each RRE
(28,49). Fully spliced mRNA is derived not only from free singly-spliced
mRNA (SN), but also from its various Rev-bound forms, SR
ðiÞ
N (where, i ¼ 1,
. . ., sn), as shown in Eq. 3. A splicing delay factor (d, dF(i), or dS(i)) describes
the extent of (direct or indirect) splicing inhibition mediated by the binding
of Rev to RNA containing the RRE, and its value ranges from 0 to 1. For d¼
0 there is minimal inhibition of splicing and Rev has no effect on the stability
of the RNA in the nucleus; instead, Rev enhances cytoplasmic expression
solely by facilitating nuclear export relative to splicing. For d ¼ 1 there is
almost complete inhibition of splicing; levels of Rev-RNA complexes in the
nucleus fall due to nuclear export or RNA degradation, not because of
splicing. Fully spliced mRNA is also subject to nuclear export (Eqs. 3 and
6), whereas free incompletely-spliced mRNAs (FN and SN) are assumed to
remain in the nucleus. The cytoplasmic pools of incompletely-spliced RNAs
(FC and SC) are instead generated by nuclear export of the corresponding
nucleic Rev-RNA complexes (FR
ðiÞ
N and SR
ðiÞ
N ), as shown in Eqs. 4 and 5
(also Eqs. 7 and 8). Unless otherwise speciﬁed, we assume that only Rev-
RNA complexes above a ﬁxed Rev threshold level (Th) are subject to
nuclear export (k
F;ðiÞ
exp ¼ kS;ðiÞexp ¼ 0; for all i, Th), where Th ¼ 7 was applied
as its base-case value, and this threshold is the same for complexes
containing full-length and singly-spliced mRNAs. Furthermore, ﬁrst-order
kinetics and the same export rate constants are assumed for all the export
processes (kMexp ¼ kF;ðiÞexp ¼ kS;ðiÞexp ; for all i $ Th). In the nucleus the ith Rev-
bound forms of incompletely-spliced mRNAs (FR
ðiÞ
N and SR
ðiÞ
N ) are in dy-
namic equilibrium with the corresponding (i  1) and (i 1 1) Rev-bound
forms (Eqs. 7 and 8), where the (i ¼ 0) species (FRð0ÞN and SRð0ÞN ) correspond
to the free mRNAs (FN and SN). Here we implemented high- and low-
afﬁnity Rev bindings by applying different Rev association (k
ðiÞ
a ) and
dissociation (k
ðiÞ
d ) constants (51) for each (i) Rev-bound form of in-
completely-spliced mRNA. Unless otherwise speciﬁed, we assumed that
only the ﬁrst Rev binding is a high-afﬁnity Rev binding, and the same rate
constants are applied to all low-afﬁnity Rev bindings. Each (i) Rev-bound
form of full-length mRNA (FR
ðiÞ
N ) is spliced, but with a delayed kinetics
characterized by dF(i), to yield the corresponding singly-spliced mRNA
(SR
ðiÞ
N ) (Eqs. 7 and 8). Then each FR
ðiÞ
N (i¼ 1, . . . , sn) is further spliced, with
delay dS(i), to yield fully spliced mRNA (MN) (Eqs. 3 and 8). In the sim-
ulation, unless otherwise speciﬁed, the same value was assumed for all the
splicing delay factors, and d¼ 0.8 was applied as its base-case value. All the
nucleic and cytoplasmic mRNAs, including both free and Rev-bound forms,
are subject to RNA degradation, and the same degradation rate constants
were assumed for all the mRNAs.
Rev and Tat proteins are expressed from their corresponding cytoplasmic
mRNAs (Eqs. 9 and 10), and Rev continuously shuttles between the nucleus
and the cytoplasm, generally with faster rates of import than export (60–62),
whereas Tat is imported to the nucleus (Eqs. 9–12). The steady-state
translation rate (Tr) was obtained by dividing a typical eukaryotic ribosome
elongation rate, 100 ;200 AA/min (2 AA/s was applied here) (80), by the
space between eukaryotic ribosomes, ;1 ribosome/80 bases (or 1 protein
product/80 bases) (71,81), in poly-ribosomal states. It has been reported that
Rev-expressing mRNA (rev mRNA) encodes both Rev and Nef proteins
(7,12,42,44), where the fraction of Rev (or probability for rev mRNA to
encode Rev), fRev, is ;0.5–0.7 (44). In contrast, Tat-expressing mRNA (tat
mRNA) encodes practically Tat protein only, where the fraction of Tat (or
probability for tat mRNA to encode Tat), fTat, is.0.998 (44). fRev¼ 0.5 and
fTat ¼ 1 were assumed in the simulation. Unless otherwise speciﬁed, the
same export rate constants were assumed for Rev and all HIV-1 mRNAs
(kRexp ¼ kMexp ¼ kF;ðiÞexp ¼ kS;ðiÞexp ; for all i $ Th), whereas the export rate of Tat
was assumed to be zero (kTexp ¼ 0). However, we assumed the same import
rate for both Rev and Tat (kRimp ¼ kTimp). Rev and Tat in both compartments
(nucleus and cytoplasm) are subject to protein degradation. It has been
reported that the half-life of Rev is signiﬁcantly shorter in the cytoplasm (4
h) than in the nucleus (16 h) (63). We assumed that the half-life of Tat was
the same as the half-life of Rev in each of the compartments (63,82). In the
cytoplasm the release of Rev from Rev-RNA complexes contributes to a
cytoplasmic pool of Rev. Because the HIV-1 growth dynamics is insensitive
to the rate of the Rev release unless it is excessively low, we modeled the
Rev release as an instantaneous process, and therefore variables for Rev-
RNA complexes in the cytoplasm were not explicitly included in the model
(Eqs. 4, 5, and 9). In the nucleus, Rev is in dynamic equilibrium with
the different Rev-bound forms of incompletely-spliced mRNA (FR
ðiÞ
N and
SR
ðiÞ
N ; i ¼ 0, . . ., sn) (Eq. 11). Rev in the nucleus is much more stable than
HIV-1 mRNAs (25,63,83), so we assumed that Rev is recycled from all the
Rev-RNA complexes (FR
ðiÞ
N and SR
ðiÞ
N ; i ¼ 1; . . . ; sn) after RNA degra-
dation, and also from Rev-bound forms of singly-spliced mRNA as they
react to form fully spliced mRNA (Eq. 11). Finally, we took that the
diameter of a T-cell nucleus to be 6 mm (54,84) when performing unit
conversion from molar concentration to the number of molecules in the
nucleus.
k
ðiÞ
d Rev dissociation constant for FR
ðiÞ
N and SR
ðiÞ
N :
kRNAdeg;N; k
RNA
deg;C RNA degradation rate constants in the nucleus and
cytoplasm, respectively.
kProdeg;N; k
Pro
deg;C Protein degradation rate constants in the nucleus and
cytoplasm, respectively.
f Stat; f
M
tat Fraction of tat mRNA in singly- and fully spliced
mRNAs, respectively.
fMrev Fraction of rev mRNA in fully spliced mRNA.
fRev Probability for rev mRNA to encode Rev.
fTat Probability for tat mRNA to encode Tat.
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APPENDIX 4: KINETIC CONSTANTS AND
PARAMETERS
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